Iovance Biotherapeutics, Inc. (IOVA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Iovance Biotherapeutics reported revenue of $263.5M, up 60.6% from $164.1M the year before. Net income was -$391.0M (a -148.4% net margin), or -$1.09 per diluted share. Gross margin was 34.3% and operating margin was -153.1%. Operating activities generated -$302.4M of cash, leaving -$336.2M of free cash flow. At fiscal year end, Iovance Biotherapeutics held $913.2M in total assets against $214.6M in total liabilities, including $163.1M of cash and equivalents.
Open the full interactive Iovance Biotherapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Iovance Biotherapeutics Key Stats
| Share Price | $14.50 |
|---|---|
| Market Cap | $6.53B |
| Revenue YoY Growth | +60.6% |
| 52-Week Range | $1.81 – $14.82 |
| Shares Outstanding | 450.2 million (basic, 2026 Q2) |
Iovance Biotherapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.2M | $164.1M | $263.5M |
| Cost of Goods Sold | — | — | — | $461.7M | $559.3M | $666.9M |
| Gross Profit | — | — | — | -$9.6M | $40.1M | $90.3M |
| Operating Income | -$261.9M | -$342.7M | -$398.9M | -$460.6M | -$395.3M | -$403.4M |
| Pre-Tax Income | -$259.6M | -$342.3M | -$395.9M | -$447.5M | -$375.0M | -$393.0M |
| Income Tax | $0 | — | — | -$3.5M | -$2.8M | -$2.1M |
| Net Income | -$259.6M | -$342.3M | -$395.9M | -$444.0M | -$372.2M | -$391.0M |
| Diluted EPS | -$1.88 | -$2.23 | -$2.49 | -$1.89 | -$1.28 | -$1.09 |
Iovance Biotherapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $67.5M | $86.8M | $71.4M | $99.3M |
| Net Income | -$91.3M | -$71.9M | -$79.0M | -$47.3M |
| Diluted EPS | — | -$0.20 | -$0.19 | -$0.11 |
Iovance Biotherapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $67.3M | $78.2M | $231.7M | $114.9M | $115.7M | $163.1M |
| Current Assets | $636.1M | $508.0M | $479.1M | $307.8M | $457.0M | $442.7M |
| Total Assets | $768.5M | $777.3M | $664.0M | $780.4M | $910.4M | $913.2M |
| Current Liabilities | $54.9M | $89.2M | $91.5M | $110.3M | $122.3M | $138.4M |
| Total Long-Term Debt | — | $1.0M | $1.0M | $1.0M | $1.0M | — |
| Total Liabilities | $112.0M | $155.7M | $164.3M | $195.7M | $200.0M | $214.6M |
| Shareholders' Equity | $656.5M | $621.7M | $499.6M | $584.6M | $710.4M | $698.6M |
Iovance Biotherapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$205.1M | -$227.9M | -$292.8M | -$361.8M | -$353.0M | -$302.4M |
| Cash From Investing | -$317.9M | $132,000 | $256.5M | -$155.2M | -$96.4M | $47.5M |
| Cash From Financing | $576.4M | $239.3M | $190.2M | $463.0M | $390.7M | $300.8M |
| Free Cash Flow | -$251.9M | -$265.5M | -$313.2M | -$384.1M | -$364.1M | -$336.2M |
Figures from Iovance Biotherapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Iovance Biotherapeutics financials page for every line item.
Iovance Biotherapeutics Company Profile
| Ticker | IOVA |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Carlos, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001425205 |
Frequently Asked Questions
What was Iovance Biotherapeutics' revenue in fiscal 2025?
Iovance Biotherapeutics (IOVA) reported revenue of $263.5M for fiscal 2025.
What is Iovance Biotherapeutics' annual revenue history?
Iovance Biotherapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $1.2M; 2024: $164.1M; 2025: $263.5M.
What was Iovance Biotherapeutics' net income in fiscal 2025?
Iovance Biotherapeutics reported net income of -$391.0M for fiscal 2025.
What was Iovance Biotherapeutics' earnings per share (EPS) in fiscal 2025?
Iovance Biotherapeutics' diluted EPS was -$1.09 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Iovance Biotherapeutics generate in fiscal 2025?
Iovance Biotherapeutics generated -$336.2M of free cash flow in fiscal 2025.
What was Iovance Biotherapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Iovance Biotherapeutics reported revenue of $99.3M.
How many shares of Iovance Biotherapeutics are outstanding?
Iovance Biotherapeutics reported a weighted average of 450.2 million basic shares outstanding in 2026 Q2.
What is Iovance Biotherapeutics' market cap?
Based on its latest closing price, Iovance Biotherapeutics (IOVA) has a market capitalization of about $6.53B.
When does Iovance Biotherapeutics' fiscal year end?
Iovance Biotherapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Iovance Biotherapeutics headquartered?
Iovance Biotherapeutics lists its business address in San Carlos, California in its SEC filings.
Iovance Biotherapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →